drug
pumitamig
Phase 3updated 6mo agoby $BNTX BioNTech SE
Phase 3community read0 votes
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying pumitamig
- phase3A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- phase2A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- phase3ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- phase2A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
- phase2A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- phase2A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- phase2A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- phase2A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
News(10)
- FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survivalThe FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.biospace · 20h ago
- FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF classThe FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…fiercebiotech · 3d ago
- BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…fiercebiotech · 6d ago
- BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD casesBioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to conclude its HER2-directed candidate may offer limited benefits in the…fiercebiotech · 22d ago
- ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drugBristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its BioNTech-partnered PD-L1xVEGF-A drug are “very promising,” as phase 3 ambitions ram…fiercebiotech · 22d ago
- Hype vs. reality: What pharma’s hottest R&D bets have actually provedNew types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.biopharma_dive · 27d ago
- BioNTech mRNA cancer immunotherapy misses first objective in key studyAn early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.biopharma_dive · 1mo ago
- Summit, BioNTech, more headline WCLC with next-gen lung cancer drugsBioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…biospace · 2mo ago
- Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial failsBMS is barreling toward a clinical trial readout that an H.C. Wainwright analyst believes could contribute to the return of mergers between mega-cap drugmakers.biospace · 2mo ago
- BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechBioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…biospace · 3mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that